For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its top-selling drug off the market.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the ...

Shares of Sarepta Therapeutics (SRPT-35.94%) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark ...

The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% ...

Sarepta Therapeutics is down 70.4% since the beginning of the year, and at $36.69 per share, it is trading 77.6% below its 52-week high of $163.85 from June 2024.

At this stage, Sarepta stock remains a high-risk, high-reward investment which may not be suitable for most investors. Unless you have a high tolerance for risk, you're better off steering clear.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.